Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
928
Shimamoto T, Tomoda A, Ishida R, Ohyashiki K.
Antitumor effects of a novel phenoxazine derivative on human leukemia cell lines in vitro and in vivoClin Cancer Res
2001
7(3):704-8
PubMed ID: 11297267
929
Tomoda A, Arai S, Ishida R, Shimamoto T, Ohyashiki K.
An improved method for the rapid preparation of 2-amino-4,4a-dihydro-4a,7-dimethyl-3H-phenoxazine-3-one, a novel antitumor agentBioorg Med Chem Lett
2001
11(8):1057-8
PubMed ID: 11327588
DOI: 10.1016/s0960-894x(01)00153-6
38
Nishimaki J, Miyazawa K, Gotoh A, Yoshikawa O, Ohyashiki K, Toyama K.
Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cellsLeuk Res
1996
20(5):415-20
PubMed ID: 8683981
DOI: 10.1016/0145-2126(96)00009-4
40
Ohyashiki JH, Ohyashiki K, Shimamoto T, Kawakubo K, Fujimura T, Nakazawa S, Toyama K.
Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expressionBlood
1995
85(12):3713-8
PubMed ID: 7780155
36
Ohyashiki K, Ohyashiki JH, Fujimura T, Kawakubo K, Shimamoto T, Saito M, Nakazawa S, Toyama K.
Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capabilityCancer Genet Cytogenet
1994
78(1):64-7
PubMed ID: 7987807
DOI: 10.1016/0165-4608(94)90047-7
39
Kawakubo K, Ohyashiki JH, Ohyashiki K, Tauchi T, Kimura N, Nakazawa S, Toyama K.
Hypomethylated status, but not RAG-1, is required for T-cell receptor-beta-chain gene rearrangement in acute leukemia cellsCancer Genet Cytogenet
1994
78(1):40-5
PubMed ID: 7987804
DOI: 10.1016/0165-4608(94)90044-2
35
Hunger SP, Ohyashiki K, Toyama K, Cleary ML.
Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemiaGenes Dev
1992
6(9):1608-20
PubMed ID: 1516826
1325
Ohyashiki K, Fujieda H, Miyauchi J, Ohyashiki, J H, Tauchi T, Saito M, Nakazawa S, Abe K, Yamamoto K, Clark, S C, et al.
Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3.Leukemia
1991
5:322-31
PubMed ID: 2027299
8398
Ikawa Y, Sugimoto N, Koizumi S, Yachie A, Saikawa Y.
Dense methylation of types 1 and 2 regulatory regions of the CD10 gene promoter in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene.J. Pediatr. Hematol. Oncol.
2010
32:4-10
PubMed ID: 20051780
DOI: 10.1097/MPH.0b013e3181c29c3c
2119
Yoshinobu Matsuo, Ayumi Okochi, Toshio Ariyasu, Emi Iimura and Tadao Ohno
Identification of Cell Lines with Variabel Numbers of Tandem Repeat(VNTR) Amplified by Polymerase Chain ReactionTiss Cult Res Commun
1996
15:211-219
DOI: 10.11418/jtca1981.15.4_21